NKF(SH:603707) Shang Hai Zheng Quan Bao·2025-06-09 20:54Group 1 - The company announced the conditional redemption of its convertible bonds, "Jianyou Convertible Bonds," allowing bondholders to sell their bonds back to the company at a price of 100.30 RMB per bond, including accrued interest [2][10][11] - The redemption period is set from June 17, 2025, to June 23, 2025, with funds to be disbursed on June 26, 2025 [3][11] - The bonds will stop converting into shares during the redemption period, but trading will continue [3][13] Group 2 - The company’s subsidiary, Meitheal Pharmaceuticals, received FDA approval for the production site transfer of Daunorubicin Hydrochloride Injection, which is used in the treatment of acute non-lymphocytic leukemia and acute lymphoblastic leukemia [15][16] - The approved product is expected to be launched in the U.S. market soon, which may positively impact the company's financial performance [18]